

Cetrorelix, Cetrotide, Ganirelix, Fyremadel

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720. If you have questions regarding the prior authorization, please contact CVS Caremark at 1-888-877-0518. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date:
Patient's ID:		Patient's Date of Birth:
Physician's Name:		
Specialty:		NPI#:
Physician Office Telephone:	Physician Office Fax:	
Referring Provider Info: ☐ Same as Re	questing Provi	der
Name:		NPI#:
Fax:		Phone:
Rendering Provider Info: Same as Re	_	
Name:		
Fax:		Phone:
		s in accordance with FDA-approved labeling, vidence-based practice guidelines.
Patient Weight:	kg	
Patient Height:	cm	
Please indicate the place of service for the	requested drug	:
☐ Ambulatory Surgical		
☐ On Campus Outpatient Hospital		☐ Pharmacy
What is the ICD-10 code?		

	 Ception Criteria Questions: What is the prescribed product? □ Cetrotide (cetrorelix acetate), Skip to Clinical Criteria Questions □ Ganirelix acetate (generic for Fyremadel), Skip to Clinical Criteria Questions □ Cetrorelix acetate (generic for Cetrotide), Continue to Question B □ Fyremadel (ganirelix acetate), Continue to Question B 			
В.	The preferred products for your patient's health plan are Cetrotide and ganirelix acetate. Can the patient's treatment be switched to one of the preferred products? Yes, Cetrotide, <i>Skip to Clinical Criteria Questions</i> . Yes, ganirelix acetate, <i>Skip to Clinical Criteria Questions</i> . No, <i>Continue to Question C</i>			
C.	What is the prescribed product? ☐ cetrorelix acetate (generic for Cetrotide), <i>Continue to Question D</i> ☐ Fyremadel (ganirelix acetate), <i>Skip to Question E</i>			
D.	. Does the patient have a documented inadequate response, contraindication or intolerable adverse event to Cetrotide <i>ACTION REQUIRED: If 'Yes'</i> , <i>please attach supporting chart note(s).</i> ☐ Yes ☐ No <i>If Yes or No, Continue to Clinical Criteria Questions</i>			
E.	Does the patient have a documented inadequate response, contraindication, or intolerable adverse event to ganirelix acetate? <i>ACTION REQUIRED: If 'Yes'</i> , <i>please attach supporting chart note(s)</i> . \square Yes \square No <i>If Yes or No, Continue to Clinical Criteria Questions</i>			
	inical Criteria Questions			
in	What is the type of procedure the patient will be undergoing? Ovulation induction (e.g., intrauterine insemination [IUI]), <i>Continue to 2</i> Assisted reproductive technology (e.g., in vitro fertilization [IVF], frozen embryo transfer [FET], gamete atrafallopian transfer [GIFT], zygote intrafallopian transfer [ZIFT], intracytoplasmic sperm injection [ICSI]), continue to 2			
	Other, please specify:, Continue to 2			
2.	. What is the intent of therapy?			
	Inhibition of premature luteinizing hormone (LH) surge, No further questions			
	Other, No further questions			

Step Therapy Override: Complete if Applicable for the state of Maryland.		Please Circle	
Is the requested drug being used to treat stage four advanced metastatic cancer?		No	
Is the requested drug's use consistent with the FDA-approved indication or the National Comprehensive Cancer Network Drugs & Biologics Compendium indication for the treatment of stage four advanced metastatic cancer and is supported by peer-reviewed medical literature?		No	
Is the requested drug being used for an FDA-approved indication OR an indication supported in the compendia of current literature (examples: AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?		No	
Does the prescribed quantity fall within the manufacturer's published dosing guidelines or within dosing guidelines found in the compendia of current literature (examples: package insert, AHFS, Lexicomp, Clinical Pharmacology, Micromedex, current accepted guidelines)?		No	
Do patient chart notes document the requested drug was ordered with a paid claim at the pharmacy, the pharmacy filled the prescription and delivered to the patient or other documentation that the requested drug was prescribed for the patient in the last 180 days?	Yes	No	
Has the prescriber provided proof documented in the patient chart notes that in their opinion the requested drug is effective for the patient's condition?	Yes	No	

Step Therapy Override: Complete if Applicable for the state of Virginia.		Please Circle	
Is the requested drug being used for an FDA-approved indication or an indication supported in the compendia of current literature (examples: AHFS, Micromedex, current accepted guidelines)?	Yes	No	
Does the prescribed dose and quantity fall within the FDA-approved labeling or within dosing guidelines found in the compendia of current literature?	Yes	No	
Is the request for a brand drug that has an AB-rated generic equivalent or interchangeable biological product available?	Yes	No	
Has the patient had a trial and failure of the AB-rated generic equivalent or interchangeable biological product due to an adverse event (examples: rash, nausea, vomiting, anaphylaxis) that is thought to be due to an inactive ingredient?	Yes	No	
Is the preferred drug contraindicated?	Yes	No	
Is the preferred drug expected to be ineffective based on the known clinical characteristics of the patient and the prescription drug regimen?	Yes	No	
Has the patient tried the preferred drug while on their current or previous health benefit plan and it was discontinued due to lack of efficacy or effectiveness, diminished effect, or an adverse event?	Yes	No	
Is the patient currently receiving a positive therapeutic outcome with the requested drug for their medical condition?	Yes	No	

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X	
Prescriber or Authorized Signature	Date (mm/dd/yy)